Related Research Articles
Zidovudine (ZDV), also known as azidothymidine (AZT), is an antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use in combination with other antiretrovirals. It may be used to prevent mother-to-child spread during birth or after a needlestick injury or other potential exposure. It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine. It can be used by mouth or by slow injection into a vein.
The AIDS Clinical Trials Group network (ACTG) is one of the largest HIV clinical trials organizations in the world, playing a major role in setting standards of care for HIV infection and opportunistic diseases related to HIV and AIDS in the United States and the developing world. The ACTG is composed of, and directed by, leading clinical scientists in HIV/AIDS therapeutic research. The ACTG is funded by the Department of Health and Human Services, National Institutes of Health through the National Institute of Allergy and Infectious Diseases.
Armenicum is a drug invented in Armenia in 1998 that its developers claim is an effective treatment for HIV infection and a number of associated diseases. No rigorously monitored clinical trials of Armenicum have been published, and most HIV experts outside of Armenia do not endorse its use.
HIV/AIDS was first diagnosed in 1981. As of year-end 2018, 160,493 people have been diagnosed with HIV in the United Kingdom and an estimated 7,500 people are living undiagnosed with HIV. New diagnoses are highest in gay/bisexual men, with an estimated 51% of new diagnosis reporting male same-sex sexual activity as the probable route of infection. Between 2009 and 2018 there was a 32% reduction in new HIV diagnosis, attributed by Public Health England (PHE) to better surveillance and education. PHE has described an "outbreak" in Glasgow amongst people who inject drugs, and has campaigns targeting men who have sex with men in London and other major cities. London was the first city in the world to reach the World Health Organization target for HIV, set at 90% of those with HIV diagnosed, 90% of those diagnosed on HAART and 90% of those on HAART undetectable. The UK as a whole later achieved the same target. Under the Equality Act 2010, it is illegal to discriminate against someone based on their HIV status in the UK.
The history of HIV/AIDS in Australia is distinctive, as Australian government bodies recognised and responded to the AIDS pandemic relatively swiftly, with the implementation of effective disease prevention and public health programs, such as needle and syringe programs (NSPs). As a result, despite significant numbers of at-risk group members contracting the virus in the early period following its discovery, Australia achieved and has maintained a low rate of HIV infection in comparison to the rest of the world.
With 1.28 percent of the adult population estimated by UNAIDS to be HIV-positive in 2006, Papua New Guinea has one of the most serious HIV/AIDS epidemics in the Asia-Pacific subregion. Although this new prevalence rate is significantly lower than the 2005 UNAIDS estimate of 1.8 percent, it is considered to reflect improvements in surveillance rather than a shrinking epidemic. Papua New Guinea accounts for 70 percent of the subregion's HIV cases and is the fourth country after Thailand, Cambodia, and Burma to be classified as having a generalized HIV epidemic.
HIV Clinical Resource is a health information service in New York State, which provides clinical information and guidance on HIV for the use of healthcare providers and patients.
Michael S. Saag is a physician and prominent HIV/AIDS researcher at the University of Alabama at Birmingham (UAB). He holds the Jim Straley Chair in AIDS Research, is Director of the Division of Infectious Disease and of the William C. Gorgas Center for Geographic Medicine, and Director of the Center for AIDS Research. He is also the founder of the 1917 Clinic, a comprehensive AIDS treatment and research center at UAB Saag is a frequent lecturer at AIDS conferences around the world and is credited with performing pioneering clinical trials for several antiretroviral drugs now in common use for HIV treatment and for first demonstrating the clinical value of "viral-load testing" in HIV/AIDS treatment. In 2009 Saag was elected chairman of the HIV Medicine Association of the Infectious Diseases Society of America. In 2019 Saag began serving on the Presidential Advisory Council on HIV/AIDS.
How to Survive a Plague is a 2012 American documentary film about the early years of the AIDS epidemic, and the efforts of activist groups ACT UP and TAG. It was directed by David France, a journalist who covered AIDS from its beginnings. France's first film, it was dedicated to his partner Doug Gould who died of AIDS-related pneumonia in 1992. The documentary was produced using more than 700 hours of archived footage which included news coverage, interviews as well as film of demonstrations, meetings and conferences taken by ACT UP members themselves. France says they knew what they were doing was historic, and that many of them would die. The film opened in selected theatres across the United States on September 21, 2012, also includes footage of a demonstration during mass at St. Patrick's Cathedral in 1989.
Patrick Spencer Cox was an American HIV/AIDS activist. He was involved in ACT UP New York and the Treatment Action Group during the height of the AIDS Crisis in New York. He helped facilitate the production of protease inhibitors, which revolutionized AIDS care in the 1990s.
Deborah Persaud is a Guyanese-born American virologist who primarily works on HIV/AIDS at Johns Hopkins Children's Center.
Mary Jane Rotheram-Borus is a licensed clinical psychologist and professor with the University of California, Los Angeles, Department of Psychiatry and Biobehavioral Sciences. Rotheram is the professor-in-residence in the Semel Institute for Neuroscience and Human Behavior. She is the Director of the Global Center for Children and Families at UCLA and the former director of the Center for HIV Identification, Prevention, and Treatment Services.
HIV in pregnancy is the presence of an HIV/AIDS infection in a woman while she is pregnant. There is a risk of HIV transmission from mother to child in three primary situations: pregnancy, childbirth, and while breastfeeding. This topic is important because the risk of viral transmission can be significantly reduced with appropriate medical intervention, and without treatment HIV/AIDS can cause significant illness and death in both the mother and child. This is exemplified by data from The Centers for Disease Control (CDC): In the United States and Puerto Rico between the years of 2014–2017, where prenatal care is generally accessible, there were 10,257 infants in the United States and Puerto Rico who were exposed to a maternal HIV infection in utero who did not become infected and 244 exposed infants who did become infected.
Janet L. Mitchell was an American physician known for her advances in perinatal HIV/AIDS treatment. During the early days of the AIDS epidemic in the U.S. Mitchell developed protocols for health treatment of pregnant women who were HIV positive or at risk for developing AIDS. She advocated against mandatory testing and testifying before Congress, she advocated in favor of an inclusive approach to health care and social services. One of her innovations derived from a study that saw a 70% decrease in HIV transmission to babies when AZT was administered to their mothers during the pregnancy.
New York City was affected by the AIDS epidemic of the 1980s more than any other U.S. city. The AIDS epidemic has been and continues to be highly localized due to a number of complex socio-cultural factors that affect the interaction of the populous communities that inhabit New York.
HPA-23, sometimes known as antimonium tungstate, is an antiretroviral drug that was used for the treatment of HIV infection. It achieved widespread publicity as an effective treatment for HIV and AIDS beginning in 1984, just one year after HIV was first identified. Later testing failed to demonstrate any efficacy and some patients suffered serious side effects from the drug, including liver failure.
Jeffrey T. Parsons is an American psychologist, researcher, and educator; he was a Distinguished Professor of Psychology at Hunter College and The Graduate Center of the City University of New York (CUNY) and was the Director of Hunter College's Center for HIV/AIDS Educational Studies & Training, which he founded in 1996. Parsons was trained as a developmental psychologist and applied this training to understand health, with a particular emphasis on HIV prevention and treatment. He was known for his research on HIV risk behaviors of gay, bisexual, and other men who have sex with men (GBMSM), HIV-related syndemics, and sexual compulsivity. He resigned his positions at CUNY on July 3, 2019, following a year-long university investigation of misconduct allegations against him.. In 2023, the U.S. Attorney's Office announced that he was required to pay a $375,000 settlement for engaging in fraud against the federal government for many years.
The first case of HIV in a woman was recorded in 1981. Since then, numerous women have been infected with the HIV/AIDS virus. The majority of HIV/AIDS cases in women are directly influenced by high-risk sexual activities, injectional drug use, the spread of medical misinformation, and the lack of adequate reproductive health resources in the United States. Women of color, LGBTQ women, homeless women, women in the sex trade, and women intravenous drug users are at an extremely high-risk for contracting the HIV/AIDS virus. In an article published by the Annual Review of Sociology, Celeste Watkins Hayes, an American sociologist, scholar, and professor wrote, "Women are more likely to be forced into survival-focused behaviors such as transactional sex for money, housing, protection, employment, and other basic needs; power-imbalanced relationships with older men; and other partnerings in which they cannot dictate the terms of condom use, monogamy, or HIV." The largest motivator to become part of the sex trade was addiction, the second largest being basic needs, and the third was to support their children/family.
Francine Cournos is Professor of Clinical Psychiatry at the Columbia University Mailman School of Public Health. Cournos is also Principal Investigator of the Northeast Caribbean AIDS Education and Training Center at the HIV Center for Clinical and Behavioral Studies.
James M. Oleske is an American pediatrician and HIV/AIDs researcher who is the emeritus François-Xavier Bagnoud (FXB) Professor of Pediatrics at Rutgers New Jersey Medical School in Newark, New Jersey. He is best known for his pioneering work in identifying HIV/AIDS as a pediatric disease, and treating and researching it beginning in the 1980s. He published one of the first articles identifying HIV/AIDS in children in JAMA in 1983 and was a co-author of one of the articles by Robert Gallo and others identifying the virus in Science in 1984.
References
- 1 2 Scott, Janny; Leslie Kaufman (July 17, 2005). "Belated Charge Ignites Furor Over AIDS Drug Trial". New York Times .
- ↑ Foderaro, Lisa (January 27, 2009). "Study Refutes Claims on AIDS Drug Trials". New York Times .
- ↑ Holmwood, Leigh (October 23, 2007). "'Serious concern' at BBC over flawed HIV film". The Guardian .
- ↑ "Summaries of upheld complaints" (PDF). BBC Editorial Complaints Unit. Retrieved March 28, 2014.